Skip to content
Clinical Trials – home
Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 44

  • 1 291 clinical trials
  • 445 recruiting
  • 379 conditions
  • 29 countries

Conditions in this area

379 conditions with trials, the busiest first

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 291 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 291 clinical trials

Infectious pleural effusion

Not yet recruiting

Early Saline Pleural Irrigation for Patients with Complicated Pleural Infections

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Centre Hospitalier Universitaire Amiens Picardie

Conjunctivitis allergic+3

Not yet recruiting

Clinical Trial of Dermatophagoides farinae, Dermatophagoides pteronyssinus, and Blomia tropicalis Allergen Extracts in Patients with Allergic Rhinitis/Rhinoconjunctivitis With or Without Mild Asthma

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Allergen extracts
  • Sponsor:Inmunotek S.L.

Vasopressin Versus Norepinephrine for Patients with Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Endarterectomy Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Fondation Hopital Saint Joseph

Hepatocellular carcinoma+5

Not yet recruiting

DB-1311 in Combination with BNT327 or DB-1305 for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:Dualitybio Inc.

Non-small cell lung cancer

Not yet recruiting

Morning Versus Afternoon Pembrolizumab, Carboplatin, and Pemetrexed in Adults With Stage IV Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Assistance Publique Hopitaux De Paris

Study of Empagliflozin, Losartan Potassium and Hydrochlorothiazide to Prevent Kidney Stones in Patients with Paraffin Oil Induced Granulomatous Disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:Region Hovedstaden

A study to evaluate the safety and effectiveness of zampilimab in people with idiopathic pulmonary fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zampilimab
  • Sponsor:Chiesi Farmaceutici S.p.A.

Interstitial lung disease+2

Not yet recruiting

Carboplatin‑based drug combination for advanced non‑small cell lung cancer patients with interstitial lung disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Seasonal allergy

Not yet recruiting

Dose-finding study of sublingual immunotherapy with phleum pratense extract (vs sodium chloride) in patients with grass pollen allergic rhinitis

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Phleum Pratense
  • Sponsor:Asac Pharmaceutical Inmunology S.A.

Non-small cell lung cancer

Not yet recruiting

A study to evaluate the safety and effectiveness of petosemtamab and pembrolizumab in adults with non-small cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merus B.V.

A study evaluating the use of semaglutide for treating obstructive sleep apnea in older adults who are overweight or have obesity

Registered drugNo placebo
Countries:SpainSpain
  • Participants:65+ years
  • Substances:Semaglutide
  • Sponsor:Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre

Pulmonary hypertension

Not yet recruiting

A study to evaluate the effectiveness of levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction.

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Levosimendan
  • Sponsor:Tenax Therapeutics Inc.

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.